荣泰健康(603579) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 400,613,890.42, representing a year-on-year increase of 3.86%[3] - Net profit attributable to shareholders for Q1 2024 was CNY 62,741,790.01, up 67.31% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 61,055,837.73, reflecting a significant increase of 136.04% year-on-year[3] - Basic earnings per share for Q1 2024 were CNY 0.47, an increase of 67.86% from the previous year[6] - The diluted earnings per share were CNY 0.42, marking a 50.00% increase compared to the same period last year[6] - Total operating revenue for Q1 2024 was CNY 400,613,890.42, an increase of 3.1% compared to CNY 385,718,637.33 in Q1 2023[18] - Net profit for Q1 2024 was CNY 62,847,346.26, up 67.0% from CNY 37,675,339.13 in Q1 2023[19] - Earnings per share for Q1 2024 were CNY 0.47, compared to CNY 0.28 in Q1 2023, reflecting a growth of 67.9%[19] - The total comprehensive income for Q1 2024 was CNY 60,953,288.76, compared to CNY 37,565,515.60 in Q1 2023, reflecting an increase of 62.1%[19] Assets and Liabilities - The company's total assets at the end of Q1 2024 were CNY 3,458,216,200.57, a 2.17% increase from the end of the previous year[4] - Shareholders' equity attributable to the parent company was CNY 2,052,718,628.07, up 4.26% from the previous year-end[4] - The company's current assets totaled RMB 2,215,838,583.92, slightly down from RMB 2,227,668,652.17 in the previous period, indicating a decrease of about 0.53%[15] - The total liabilities decreased slightly to CNY 1,401,289,501.59 in Q1 2024 from CNY 1,411,896,901.04 in Q1 2023[18] - The total equity attributable to shareholders increased to CNY 2,052,718,628.07 in Q1 2024 from CNY 1,968,889,002.67 in Q1 2023, marking a growth of 4.3%[18] - The company's total liabilities increased, with current liabilities including accounts payable reported at RMB 316,274,915.78, down from RMB 391,912,802.51, showing a decrease of about 19.25%[15] Cash Flow - The net cash flow from operating activities was negative CNY 150,370,360.33, a decline of 813.40% year-on-year, primarily due to increased payments for goods[3][5] - Cash received from sales and services in Q1 2024 was approximately $387.49 million, a decrease from $392.97 million in Q1 2023, reflecting a decline of about 1.9%[22] - Net cash flow from operating activities was negative at approximately -$150.37 million, compared to a positive cash flow of $21.08 million in the same quarter last year[22] - Total cash inflow from investment activities was approximately $244.17 million, an increase from $237.99 million in Q1 2023[22] - Cash outflow from investment activities increased significantly to approximately $332.61 million, compared to $194.99 million in Q1 2023, resulting in a net cash flow from investment activities of approximately -$88.45 million[22] - Cash inflow from financing activities was approximately $265.55 million, a substantial increase from $49.13 million in Q1 2023[23] - Net cash flow from financing activities was approximately $163.43 million, compared to a negative cash flow of -$148.50 million in the same quarter last year[23] - The ending cash and cash equivalents balance for Q1 2024 was approximately $1.31 billion, down from $1.24 billion in Q1 2023[23] - The company reported a significant increase in cash received from tax refunds, totaling approximately $32.51 million, compared to $18.05 million in Q1 2023, marking an increase of about 80%[22] - Total cash outflow from operating activities was approximately $585.14 million, compared to $427.02 million in Q1 2023, indicating an increase of about 37%[22] - The company experienced a cash decrease of approximately $74.44 million in Q1 2024, compared to a decrease of $87.03 million in Q1 2023[23] Legal Matters - The company reported a legal case where it was ordered to pay RMB 5.1 million in damages related to patent infringement, with ongoing appeals indicating potential future financial implications[12] - The company has taken legal actions in response to the lawsuit, indicating proactive measures to mitigate potential financial losses[12] Research and Development - Research and development expenses rose to CNY 20,142,315.83 in Q1 2024, up from CNY 17,233,671.42 in Q1 2023, indicating an increase of 11.1%[18]